April 23, 2021
Selecting a First-in-Class Oral Therapy for Patients With HR+/HER2- Metastatic Breast Cancer
Speaker: Gena Volas-Redd, MD
Supported by: Pfizer
An Individualized Approach: A CDK4 & 6 Inhibitor For Women With Reduced Survival in HR+, HER2- MBC
Speaker: Laila Agrawal, MD
Supported by: Lilly
April 24, 2021
The only once-daily, oral maintenance therapy for all first-line platinum responders with advanced ovarian cancer, regardless of biomarker status
Speaker: Matt Anderson, MD, PhD
Supported by: GSK
Maintenance Therapy in Advanced Ovarian Cancer: Results From Key Clinical Trials
Speaker: Sharyn Lewin, MD, FACS, FACOG
Supported by: AstraZeneca
Industry-led lectures will be conducted in conjunction with this event to provide promotional product-specific information on available agents and products in development.
The above commercial program is not a part of Great Debates & Updates in Women's Oncology. It is not organized or endorsed by Imedex.
*All times subject to change.